PROVENGE® + Sipuleucel-T for Metastatic Castrate-Resistant Prostate Cancer
This study is looking at men with metastatic castrate-resistant prostate cancer (mCRPC), which is prostate cancer that has spread and no longer responds to hormone therapy. It's testing if a single booster infusion of Sipuleucel-T, an immunotherapy, can improve the immune response in patients who have already received PROVENGE®. The main goal is to see how the immune system reacts to specific proteins (PAP and PA2024) after this booster. You might be able to join if you are a man aged 18 or older, have mCRPC that is asymptomatic or minimally symptomatic, and have already qualified for and received PROVENGE® treatment. The study is currently recruiting patients.
- Study design
- This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 400 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your immune response will be measured after the booster infusion, and you will be followed for overall survival for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
At a glance
Conditions
Where it's being run
31 sites across 18 statesStudy leadership
- Nadeem Sheikh, PhD · STUDY_DIRECTOR · Dendreon Pharmaceuticals, LLC
- Benjamin Lowentritt, MD · STUDY_CHAIR · Chesapeake Urology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assess humoral immune response to PAP and PA2024 after booster infusionOnce all subjects have completed the study through the 5 year Overall Survival Period
To assess the humoral response ((i.e. antibody titer) to PAP and PA2024 after booster infusion in subjects with metastatic castrate-resistant prostate cancer who have received a single booster dose of sipuleucel-T vs those subjects who have not